News | Atrial Fibrillation | October 23, 2017

UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care

Afib hospitalizations reduced by 30 percentage points in first year of program

UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care

October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.7 million grant from the Bristol-Myers Squibb Foundation to further innovate a care model that reduced hospitalizations for atrial fibrillation (Afib) patients presenting in the emergency room by more than 30 percentage points in its first year.

Atrial fibrillation, which affects more than 2.7 million Americans, is characterized by an irregular heartbeat and is associated with an increased risk for blood clots, stroke, heart failure and multiple other heart complications according to Gehi, who serves as associate professor of medicine at the UNC School of Medicine, program director of UNC’s Clinical Cardiac Electrophysiology Fellowship.

The three-year grant from the Bristol-Myers Squibb Foundation will enable Gehi to continue development of a new protocol he established at UNC Medical Center in 2015 through a pilot grant from the UNC Center for Health Innovation and adapt and evaluate its application primary care and urgent care settings as well.

“When we launched the pilot in 2015, we realized that many Afib patients were hospitalized unnecessarily, which certainly drives up the cost of healthcare for patients, and these hospitalizations didn’t necessarily improve quality of care,” Gehi said. “We felt that one of the major problems with Afib care was that it is very disorganized. Patients bounce around between many different providers – primary care providers, cardiologists, electrophysiologists, emergency medicine physicians. There’s just not very good coordination of care for these patients.”

As a result, there is very little emphasis on education and prevention, which is critical in managing a chronic condition like Afib, Gehi explained.

“I always tell my patients: I may never be able to cure you of your atrial fibrillation, but I can work with you to manage it so that it doesn’t affect your life,” Gehi said. “We teach patients the importance of stroke prevention. We teach them how to tell when they’re in atrial fibrillation, and we teach them what they can do themselves – when they need to seek medical attention and when they can manage it on their own. It’s about getting patients more engaged in their own health.”

For many Afib patients – particularly those in vulnerable populations – access to specialty care can be extremely limited. Gehi hopes this grant can improve and perhaps remedy the lack of access in areas in and around the Triangle, Rocky Mount and High Point through partnerships with UNC Hospitals Hillsborough campus, UNC Rex Healthcare, Nash Health Care and High Point Regional Hospital.

“We’re trying to address the problem of poor access by setting up a new pathway for care for patients who have the most challenging and urgent medical needs, primarily those who are coming into the emergency room,” Gehi said. “We have set up a new pathway here at UNC Medical Center by developing a new protocol for the emergency room so that ER physicians can triage Afib patients. Those patients who aren’t particularly high-risk for poor outcomes might be discharged from the ER and sent to an Afib transition clinic.”

The Afib clinic at UNC is located at UNC Cardiology’s Meadowmont clinic in Chapel Hill. It is staffed by clinical pharmacists, though the protocol provides for any advanced practice provider to be able to staff the clinic.

“One of the things that’s so novel about our protocol is that our clinic is staffed with clinical pharmacists trained in the management of chronic illnesses, like diabetes or Afib,” Gehi said. “They are able to see these patients on a next-day basis and are able to do a lot of the patient education, which has been missing from traditional care models. They can also coordinate Afib care across all the patient’s providers.”

The 30 percentage-point reduction in hospitalizations in 2015 demonstrated that Afib can be treated in an outpatient setting for most patients, despite the statistic that upwards of 80 percent of Afib patients who go to the ER throughout the country are hospitalized, Gehi said.

“We were able to get that number down in the 50 percent range, and with further education we should be able to reduce it even further,” Gehi said. “We are quite certain we have improved the quality of care for these patients, as well.”

The Bristol-Myers Squibb Foundation grant will allow Gehi to expand this program throughout the UNC Health Care system, and potentially into other clinics and hospitals in North Carolina and across the country.

“The grant proposal was to establish other Afib clinics like the one we did here, targeting areas with a high proportion of vulnerable patients and to train local providers how to triage the patients and which ones would be appropriate to send to our clinics,” Gehi said. “Our hope is that with this type of expansion, we can show that this model is scalable, and we’ll have a larger number of patients to demonstrate outcomes in better patient care, reduced emergency room visits, and reduced hospitalizations.

“We want this to be something that can be integrated into what is already present at other hospitals and primary care and specialty care clinics. It’s beneficial to patients, beneficial to the ER, and it’s beneficial to the providers.”

For more information: www.unchealthcare.org

Related Atrial Fibrillation Content

VIDEO: The Current State of Atrial Fibrillation Ablation Technologies

Expert Consensus Released on Catheter, Surgical Ablation of Atrial Fibrillation

What is New in Electrophysiology Technologies

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.

 

 

Feature | Atrial Fibrillation | November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init